Company profile: Septerna
1.1 - Company Overview
Company description
- Provider of GPCR-focused drug discovery platforms and services, including a Native Complex Platform that reproduces receptors outside cells, enabling discovery for previously undruggable GPCRs; GPCR affinity screening; structural biology using cryo-EM; and in silico screening, plus small-molecule discovery programs targeting well-validated GPCRs across multiple therapeutic areas.
Products and services
- Native Complex Platform: Custom-engineered platform reproducing GPCRs with native structure and function outside of cells, enabling drug discovery for previously undruggable GPCRs
- Small Molecule Drug Discovery Programs: Mechanism-driven pipeline focusing on novel mechanistic approaches to well-validated GPCR drug targets across multiple therapeutic areas
- GPCR Structural Biology: Cryo-electron microscopy-based analyses revealing how molecules alter receptor function at the atomic level, aiding structure-guided drug design decisions on GPCR targets
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Septerna
DST Diagnostische Systeme
HQ: Germany
Website
- Description: Provider of in-vitro diagnostic tests and products for allergy and food intolerance, developing, manufacturing and marketing laboratory and point-of-care systems. Offerings include sIgE rapid tests, LIA ALLERGY LINE kits, NutriSMART rapid tests, NutriLAB ELISA kits, over 600 allergen extracts for diagnostic use and IVD manufacturers, and laboratory services with reports and dietary recommendations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DST Diagnostische Systeme company profile →
ARS Pharma
HQ: United States
Website
- Description: Provider of pharmaceutical research and development specializing in anti-allergy drugs; operates as a stealth pharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ARS Pharma company profile →
Abintus Bio
HQ: United States
Website
- Description: Provider of in vivo immune cell reprogramming solutions, offering programs for highly selective gene expression targeting—using synthetic biology to target specific cell types or states across gene delivery systems—for applications in leukemia, solid tumors, autoimmune, infectious, and genetic diseases, and simultaneous engineering of innate and adaptive immune cells for lymphoma and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abintus Bio company profile →
Cellenkos
HQ: United States
Website
- Description: Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellenkos company profile →
Mount Tam Biotech
HQ: United States
Website
- Description: Provider of services to develop, optimize, and bring to market novel pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mount Tam Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Septerna
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Septerna
2.2 - Growth funds investing in similar companies to Septerna
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Septerna
4.2 - Public trading comparable groups for Septerna
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →